TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.0200nMAssay Description:Inhibition of PRMT5 (unknown origin)More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.15E+3nMAssay Description:Inhibition of PRMT5 (unknown origin) using [3H]SAM after 1 hr by scintillation proximity assayMore data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataKi: 2.00E+3nMAssay Description:Covalent inhibition of human PRMT5 assessed as initial binding constant by LC-MS analysisMore data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataKi: 8.00E+3nMAssay Description:Covalent inhibition of human PRMT5 assessed as initial binding constant by LC-MS analysisMore data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.90E+4nMAssay Description:Covalent inhibition of human PRMT5 assessed as initial binding constant by LC-MS analysisMore data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataKi: 3.60E+4nMAssay Description:Covalent inhibition of human PRMT5 assessed as initial binding constant by LC-MS analysisMore data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataKi: 4.20E+4nMAssay Description:Covalent inhibition of human PRMT5 assessed as initial binding constant by LC-MS analysisMore data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataKi: 4.90E+4nMAssay Description:Covalent inhibition of human PRMT5 assessed as initial binding constant by LC-MS analysisMore data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataKi: 5.80E+4nMAssay Description:Covalent inhibition of human PRMT5 assessed as initial binding constant by LC-MS analysisMore data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataKi: 7.80E+4nMAssay Description:Covalent inhibition of human PRMT5 assessed as initial binding constant by LC-MS analysisMore data for this Ligand-Target Pair